Cargando…
The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines
BACKGROUND: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide. Up to 80% of cancer patients are classified as non-small-cell lung cancer (NSCLC) and cisplatin remains as the gold standard chemotherapy treatment, despite its limited efficacy...
Autores principales: | Cirigliano, Stéfano M., Díaz Bessone, María I., Berardi, Damián E., Flumian, Carolina, Bal de Kier Joffé, Elisa D., Perea, Silvio E., Farina, Hernán G., Todaro, Laura B., Urtreger, Alejandro J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374619/ https://www.ncbi.nlm.nih.gov/pubmed/28373828 http://dx.doi.org/10.1186/s12935-017-0413-y |
Ejemplares similares
-
Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization
por: Gottardo, Maria F., et al.
Publicado: (2020) -
CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition
por: Rosales, Mauro, et al.
Publicado: (2022) -
Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specifc cell-permeable peptide inhibitor
por: Martins, Leila R., et al.
Publicado: (2013) -
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
por: Rosales, Mauro, et al.
Publicado: (2021) -
CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
por: Ramón, Ailyn C., et al.
Publicado: (2022)